Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of XKH004 in Moderate-to-Severe Active Ankylosing Spondylitis
ChiCTR2600124334Phase 3Completed
- Sponsor
- Shanghai Changzheng Hospital
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ankylosing spondylitis (AS) comparing XKH004 arm with Placebo arm (2 arms). Primary endpoint: ASAS40 response at Week 16. Started May 2026; status: completed.
02
Drugs
lzm012
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on ChiCTR2600124334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124334.